Immunicum submits the final report for its phase I/II trial in metastatic renal cell carcinoma

Immunicum® AB (publ) today submitted the final report to the Swedish Medical Products Agency regarding its clinical phase I/II study in 12 patients with newly diagnosed kidney cancer, treated with the cancer vaccine INTUVAX®. No vaccine-related serious adverse events were noted and the report presents a hitherto achieved median survival for patients with poor prognosis that clearly exceeds the expected median survival for patients treated with established drugs.04/01/2014
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news